RGLS earnings

Topline data from an interim analysis of the fourth cohort of its Phase 1b Multiple-Ascending Dose (MAD) clinical trial showed continued mechanistic dose response Exploratory results of imaging-based biomarkers continued to show reduction in height-adjusted total kidney volume (htTKV) growth rate Successful End-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) with agreement on key components of a Phase 3 single pivotal trial for potential Accelerated Approval Company to hold conference call at 8:30 a.m. ET today SAN DIEGO, Jan. 29, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovati

Continued mechanistic dose response observed following completion of 3 mg/kg dose level based on urinary biomarker analyses Percent change from baseline in PC1 and PC2 demonstrated a dose response across all doses tested, with statistical significance seen at 3 mg/kg compared to placebo Exploratory imaging analyses indicated reduction in total kidney volume in 70% of patients dosed with 3 mg/kg  Fourth cohort enrollment underway  Company to hold conference call at 8:30am ET today SAN DIEGO, June 24, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "R

Mechanistic dose response observed at a 2mg/kg dose level based on urinary biomarker analyses Encouraging exploratory results of imaging-based biomarkers with greatest reductions in total kidney volume seen in patients with the highest increases in PC1 and PC2 Cohort 3 fully enrolled with data readout anticipated in mid-2024; Cohort 4 screening to start in 2Q 2024 Company to hold conference call at 8:30am ET today SAN DIEGO, March 12, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced positive topline results from the second

Statistically significant increase in urinary polycystin 1(PC1) after treatment with RGLS8429 Urinary polycystin exhibits anticipated pharmacokinetics/pharmacodynamics (PK/PD) correlation in patients with ADPKD Company to hold conference call at 8:30 a.m. EDT today SAN DIEGO, Sept. 20, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced positive topline results from the first cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD.

Company announced first patient dosed in its Phase 1b Multiple-Ascending Dose (MAD) study of RGLS8429 in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) Company announced positive topline safety and pharmacokinetic (PK) data from its Phase 1 Single-Ascending Dose (SAD) study of RGLS8429 in healthy volunteers for the treatment of ADPKD   $4.5 million in net proceeds in At-the-Market (ATM) sale to a new institutional investor SAN DIEGO, Nov. 10, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial res

SAN DIEGO, Nov. 3, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it will report its third quarter 2022 financial results on Thursday, November 10, 2022, after the U.S. financial markets close. In connection with the earnings release, Regulus' management team will host a live conference call and webcast on the same day at 5:00 PM ET, to discuss the Company's financial results and provide a corporate u

IND accepted and first subject dosed in the Phase 1 Single-Ascending Dose (SAD) study of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) RGLS8429 granted Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) Scientific leadership strengthened with the appointment of Amin Kamel, Ph.D., as Vice President, Drug Metabolism and Pharmacokinetics (DMPK) SAN DIEGO, Aug. 11, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the second quarter ended Jun

SAN DIEGO, Aug. 4, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it will report its second quarter 2022 financial results on Thursday, August 11, 2022, after the U.S. financial markets close. In connection with the earnings release, Regulus' management team will host a live conference call and webcast on the same day at 5:00 PM ET, to discuss the Company's financial results and provide a corporate up

FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for Autosomal Dominant Polycystic Kidney Disease (ADPKD) On track to initiate Phase 1 study in second quarter 2022 SAN DIEGO, May 12, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.  "The year is off to a great start as we continue to advance

SAN DIEGO, March 10, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced its financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.  "Last year was a transformational year for Regulus with the accomplishments in our ADPKD program including clinical validation of the target and the prioritization and advancement of our next generation compound RGLS8429," comme

SAN DIEGO, March 3, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has scheduled its fourth quarter and year-end 2021 financial results conference call and webcast on Thursday, March 10, 2022, after the U.S. financial markets close. In connection with the earnings release, Regulus' management team will host a live conference call and webcast at 5:00 PM ET on Thursday, March 10, 2022, to discuss th

SAN DIEGO, Nov. 10, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.  "We are pleased with the progress we have made in advancing our next generation candidate RGLS8429 as a potential treatment for ADPKD, as the compound has been shown to have the favorable properties of RGLS4326 without the limitations of the f

SAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it will report financial results and highlights for the quarter ended September 30, 2021 on Wednesday, November 10, 2021, after the U.S. financial markets close.  The Company will host a conference call and live audio webcast on Wednesday, November 10, 2021 at 5:00 p.m. Eastern Daylight Time to report its third quarter 2021 financial r

SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the prioritization of its promising, next-generation candidate, RGLS8429, for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The Company recently completed the dosing period of the in-life portion of the IND-enabling toxicity studies for RGLS8429; anticipates submitting an Investigational New Drug application (IND); and subject to U.S. Food and Drug Administration (FDA) clearance, initiating a phase 1 study in the second quarter of

SAN DIEGO, Aug, 3, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it will report financial results and highlights for the quarter ended June 30, 2021 on Tuesday, August 10, 2021, after the U.S. financial markets close.  The Company will host a conference call and live audio webcast on Tuesday, August 10, 2021 at 5:00 p.m. Eastern Daylight Time to report its second quarter 2021 financial results and p